Abstract: The battery disclosed here comprises one or more wound electrode bodies each composed of a strip-shaped first electrode plate and a strip-shaped second electrode plate superimposed and wound together with a strip-shaped separator between the two, and a battery case containing the wound electrode body or bodies. The first electrode plate has multiple electrode tabs protruding from an edge extending in the longitudinal direction, and the multiple electrode tabs include a first electrode tab having a straight part that is roughly perpendicular to the edge and has a length of at least 2 mm in the direction orthogonal to the edge, and second electrode tabs lacking the straight part.

Abstract: A vehicle includes: a vehicle body; at least one state sensor that is supported by the vehicle body and detects state values that are parameters related to states of the vehicle; a communicator supported by the vehicle body; at least one memory supported by the vehicle body; and processing circuitry supported by the vehicle body. The processing circuitry is configured to: store in the memory the state values detected by the state sensor with a predetermined detection cycle; extract, every predetermined set time that is longer than the detection cycle, some of the state values stored within the set time such that the extracted state values include a largest value and a smallest value among the state values stored within the set time; and transmit the extracted state values through the communicator to an external device.

Abstract: Provided are a chlorosilicate fluorescent material having high light emission efficiency, a method for producing the same, and a light emitting device. In certain embodiments, the chlorosilicate fluorescent material has a chemical composition comprising Ca, Eu, Mg, Si, O, and Cl, wherein when a molar ratio of Si in 1 mol of the chemical composition is set as 4, the chlorosilicate fluorescent material comprises Ca in a molar ratio range of 7.0 or more and 7.94 or less, Eu in a molar ratio range of 0.01 or more and 1.0 or less, Ca and Eu in a total molar ratio range of 7.70 or more and 7.95 or less, Mg in a molar ratio range of 0.9 or more and 1.1 or less, and Cl in a molar ratio range of more than 1.90 and 2.00 or less.

Abstract: A blood pressure controlling apparatus includes an acquiring part configured to acquire biological information indicating blood pressure of a subject, a producing part configured to produce a frequency modulated pulse train on the basis of the biological information, and a supplying part configured to supply an electrical current on the basis of the frequency modulated pulse train, to an electrode attached on the subject. The electrical current stimulates baroreceptor afferent nerves of the subject.

Abstract: A method of analyzing blood coagulation in vitro, comprising analyzing blood coagulation ability using a blood sample in which an extrinsic blood coagulation activator, thrombomodulin and a heparin-like substance are added.

Abstract: A method for manufacturing a micro chip is for liquid sample analysis and has a flow path therein. The method includes preparing a base material having, in a surface thereof, a groove serving as a flow path, preparing a film which covers the surface of the base material to seal the groove and can thus form a flow path, applying, on the base material, an adhesive and/or a sticking agent, and attaching the film onto the base material so that a surface of the base material, to which the adhesive and/or the sticking agent is applied, and the film overlap each other. The attaching includes pressure-bonding the film and the base material under 32-643 kPa, and curing the adhesive and/or the sticking agent.

Abstract: A method of evaluating extrinsic blood coagulation ability in vitro, characterized in that a contact factor inhibitor and an inhibitor for a tissue factor pathway inhibitor (TFPI) are added to a blood sample to evaluate blood coagulation ability, and a method of evaluating intrinsic blood coagulation ability in vitro, characterized in that both the contact factor inhibitor and an extrinsic blood coagulation inhibitor are added to a blood sample to evaluate blood coagulation ability.

Abstract: A method for manufacturing a microchip for a blood coagulation test includes preparing a substrate which has, in the surface thereof, a groove serving as a flow channel, and has a first through-hole serving as an inlet and provided on one end side of the groove. A film having a surface coated with collagen and/or tissue thromboplastin is prepared so as to cover a region of a portion on the flow channel when the film is bonded to the surface, of the substrate, having the groove therein overlaps the surface, of the film, coated with the collagen and/or tissue thromboplastin.

Abstract: A method for manufacturing a microchip for analyzing a component in a liquid sample by passing the sample through a flow path provided inside and performing a reaction in a reaction portion provided in a portion of the flow path, the method including: a step of providing a substrate including on the surface thereof a groove serving as a flow path and a reaction portion in a portion between the both ends of the groove; a step of applying an adhesive agent or a gluing agent on an area other than the groove on the grooved surface of the substrate; a step of providing a film on an area of which a reaction substance is applied; and a step of attaching the film on the substrate in a specific manner.

Abstract: A pulmonary embolism diagnosis support apparatus includes a hardware processor that: obtains a dynamic image of a chest of an examinee captured through radiographic dynamic imaging; analyzes blood flow in the dynamic image to generate blood flow information; generates background lungs information regarding background lungs of the examinee; automatically generates diagnosis support information regarding pulmonary embolism, based on the blood flow information and the background lungs information; and outputs the diagnosis support information regarding pulmonary embolism.

Abstract: A method for analyzing thrombogenic capacity or blood coagulation capacity, the method comprising adding calcium, a blood coagulation factor XII (FXII) inhibitor, and a kallikrein inhibitor to blood collected with a blood collection tube containing sodium citrate, to allow initiation of blood coagulation reaction, is provided. Preferably, heparin, heparan sulfate, and tissue factor are further added to the blood, and thrombogenic capacity or blood coagulation capacity is analyzed.

Abstract: A blood pressure controlling apparatus includes an acquiring part configured to acquire biological information indicating blood pressure of a subject, a producing part configured to produce a frequency modulated pulse train on the basis of the biological information, and a supplying part configured to supply an electrical current on the basis of the frequency modulated pulse train, to an electrode attached on the subject. The electrical current stimulates baroreceptor afferent nerves of the subject.

Abstract: A blood coagulation test device includes: a container into which a test-object blood is placed; a stirring part for stirring the test-object blood in the container; an elastic body being connected to the stirring part and capable of deforming in response to a force received through stirring of the test-object blood from the stirring part; a control unit for transmitting a predetermined rotary motion to the stirring part and causing the stirring part to rotate in a reciprocating manner in a circumferential direction by rotating the elastic body in a reciprocating manner about an axis of the stirring part as a rotation axis and controlling the reciprocating rotation at a position separated by a predetermined diameter from the rotational axis; and a measurement unit for measuring a rotation angle pertaining to the reciprocating rotation of the stirring part.

Abstract: The present invention addresses a problem in which, when examining blood properties in measurements of thrombus formation capacity and platelet function or the like, measurement data is changed as a result of sedimentation of blood in reservoirs during measurement. An erythrocyte membrane ion transport inhibitor, such as disodium 4,4?-dinitrostilbene-2,2?-disulfonate (DNDS) or 4,4?-diisothiocyanatostilbene-2,2?-disulfonic acid (DIDS), is used to inhibit erythrocyte sedimentation, and accurate measurement data is obtained.

Abstract: A microchip for testing a blood property, comprising first and second channels for allowing a blood sample(s) to flow inside, wherein the first channel has a first reaction section coated with collagen and tissue thromboplastin; and said second channel has a second reaction section, wherein the second section has been coated with collagen and tissue thromboplastin the amount of which is equivalent to or smaller than the amount of tissue thromboplastin on said first channel, or the second section has been coated with collagen but not with tissue thromboplastin.

Abstract: A blood coagulation test device includes: a container into which a test-object blood is placed; a stirring part for stirring the test-object blood in the container; an elastic body being connected to the stirring part and capable of deforming in response to a force received through stirring of the test-object blood from the stirring part; a control unit for transmitting a predetermined rotary motion to the stirring part and causing the stirring part to rotate in a reciprocating manner in a circumferential direction by rotating the elastic body in a reciprocating manner about an axis of the stirring part as a rotation axis and controlling the reciprocating rotation at a position separated by a predetermined diameter from the rotational axis; and a measurement unit for measuring a rotation angle pertaining to the reciprocating rotation of the stirring part.

Abstract: A method for analyzing thrombogenic capacity or blood coagulation capacity, the method comprising adding calcium, a blood coagulation factor XII (FXII) inhibitor, and a kallikrein inhibitor to blood collected with a blood collection tube containing sodium citrate, to allow initiation of blood coagulation reaction, is provided. Preferably, heparin, heparan sulfate, and tissue factor are further added to the blood, and thrombogenic capacity or blood coagulation capacity is analyzed.

Abstract: A circulation time measurement device includes: a signal acquisition unit that acquires an air flow signal indicating a temporal change of an air flow of breathing and an oxygen saturation signal indicating a temporal change of oxygen saturation; and a circulation time calculation unit that measures an oxygen delivery circulation time of blood based on a time difference between a predetermined first time in the air flow signal and a second time in the oxygen saturation signal indicating an increase in oxygen saturation corresponding to resumption of breathing at the first time.

Abstract: A microchip for testing a blood property, comprising first and second channels for allowing a blood sample(s) to flow inside, wherein the first channel has a first reaction section coated with collagen and tissue thromboplastin; and said second channel has a second reaction section, wherein the second section has been coated with collagen and tissue thromboplastin the amount of which is equivalent to or smaller than the amount of tissue thromboplastin on said first channel, or the second section has been coated with collagen but not with tissue thromboplastin.